Table 1.
Patient characteristics
| Adjuvant radiochemotherapy n (%) | Neoadjuvant radiochemotherapy n (%) | All n (%) | |
| Gender | |||
| Female | 148 (63.5) | 38 (71.7) | 186 (65.0) |
| Male | 85 (36.5) | 15 (28.3) | 100 (35.0) |
| Age | |||
| ≤Median age of 62 yr | 134 (57.5) | 32 (60.4) | 166 (58.0) |
| > Median age of 62 yr | 99 (42.5) | 21 (39.6) | 120 (42.0) |
| Tumor location | |||
| Upper third | 35 (15.1) | 0 (0.0) | 35 (12.2) |
| Middle third | 100 (42.9) | 23 (43.4) | 123 (43.0) |
| Lower third | 87 (37.3) | 25 (47.2) | 112 (39.2) |
| Not known | 11 (4.7) | 5 (9.4) | 16 (5.6) |
| Surgical Resection | |||
| Anterior (LAR) | 133 (56.8) | 13 (24.6) | 146 (51.0) |
| Abdominoperineal (APR) | 100 (43.2) | 40 (75.4) | 140 (49.0) |
| R status | |||
| R0 | 197 (84.5) | 37 (69.8) | 234 (81.8) |
| R1 | 17 (7.3) | 5 (9.4) | 22 (7.7) |
| R2 | 4 (1.8) | 2 (3.8) | 6 (2.1) |
| not known | 15 (6.4) | 9 (17.0) | 24 (8.4) |
| Stage | |||
| II | 75 (32.2) | 17 (32.1) | 92 (32.2) |
| III | 158 (67.8) | 36 (67.9) | 194 (67.8) |
| N stage | |||
| N0 | 74 (31.8) | 17 (32.1) | 91 (31.8) |
| N1 | 81 (34.8) | 27 (50.9) | 108 (37.8) |
| N2 | 78 (33.4) | 9 (17.0) | 87 (30.4) |
| Grading | |||
| G I | 11 (4.7) | 9 (17.0) | 20 (7.0) |
| G II | 161 (69.1) | 29 (54.7) | 190 (66.5) |
| G III | 44 (18.9) | 9 (17.0) | 53 (18.5) |
| Not known | 17 (7.3) | 6 (11.3) | 23 (8.0) |
| CEA | |||
| < 3 ng/mL | 102 (43.8) | 16 (30.2) | 118 (41.3) |
| ≥ 3 ng/mL | 102 (43.8) | 16 (30.2) | 118 (41.3) |
| Not known | 29 (12.4) | 21 (39.6) | 50 (17.4) |
| RTOG | |||
| RTOG 0 | 96 (41.2) | 30 (56.6) | 126 (44.1) |
| RTOG I | 75 (32.2) | 14 (26.4) | 89 (31.1) |
| RTOG II | 46 (19.7) | 9 (17.0) | 55 (19.2) |
| RTOG III | 13 (5.6) | 0 (0.0) | 13 (4.6) |
| RTOG IV | 3 (1.3) | 0 (0.0) | 3 (1.0) |
| RTOG V | 0 (0.0) | 0 (0.0) | 0 (0.0) |